TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06239311
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Solution for injection in prefilled pen
Study: NCT06239311
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Solution for injection in prefilled pen
Study: NCT04718064
Drug: placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: placebo once daily, for three consecutive days,
Study: NCT04670653
Drug: MAGNÓLIA NASAL GEL
Normalized name: Magnolia champaca flower oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Magnólia nasal gel spray
Study: NCT05850377
Drug: 5-Aminolevulinic Acid (5-ALA) Gliolan®
Approvals — FDA: no, EMA: no, PMDA: no
Description: Gliolan® is presented as a powder for oral solution in 60 ml colorless glass vials and is administered orally three hours (range 2-4 hours) before anaesthesia. One bottle contains 1.17 g of 5-aminolevulinic acid (5-ALA), corresponding to 1.5 g 5-aminolevulinic acid hydrochloride (5-ALA HCl). The recommended dose is 20 mg 5-ALA HCl per kilogram body weight. One ml of reconstituted solution contains 23.4 mg of 5-ALA, corresponding to 30 mg 5-ALA HCl.
Study: NCT05008887
Drug: Methotrexate
Normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Fractional CO2 laser-assisted cutaneous delivery of methotrexate solution in stable, non-segmental vitiligo
Study: NCT04788563
Drug: Original antihypertensive treatment (preference selection arm)
Approvals — FDA: no, EMA: no, PMDA: no
Description: In this group, patients will maintain their original antihypertensive treatment.
Study: NCT04933630
Drug: FDA-approved selective-serotonin reuptake inhibitors (SSRIs) and selective-norepinephrine reuptake inhibitors (SNRIs)
Normalized name: Selective serotonin reuptake inhibitors
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants exiting the TRAIT study will have received a 90-day supply of their current protocol-approved antidepressant treatment (ADT) if clinically appropriate, prior to entering the TRAIT-RS study, in addition to a continuity of care letter to be given to their medical provider to facilitate a refill of that medication as desired. (See NCT04748276 for specific formulary and prescribing guidelines).
Study: NCT04884243
Drug: CBT-006
Approvals — FDA: no, EMA: no, PMDA: no
Description: ophthalmic solution
Study: NCT05032508
Drug: Lidocaïne Aguettant 20 mg/ml
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lidocaïne Aguettant 20 mg/ml, injectable solution, applied to the skin with an impregnated compress, applied 15 minutes before infiltration performed by an experienced operator.
Study: NCT05032508
Drug: NaCl 0,9%
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo (NaCl 0,9%), applied to the skin with an impregnated compress, applied 15 minutes before infiltration performed by an experienced operator.
Study: NCT06184698
Drug: LV
Normalized name: VALVE
Approvals — FDA: no, EMA: no, PMDA: no
Description: 5-FU 2400 mg/m²
Study: NCT04015557
Drug: Acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Adult patients with homocystinuria due to cystathionine beta synthase (CBS) deficiency and controls will receive a single dose of Acetaminophen (1.5g) orally. Blood will be drawn at time 0, 2, 4, 6 and 8 hours after the acetaminophen dose to measure liver enzymes and markers of oxidative stress.
Study: NCT04676243
Drug: Treatment according to Physician's Choice
Approvals — FDA: no, EMA: no, PMDA: no
Description: Usually daunorubicin/ cytarabine or idarubicin/Cytarabine plus FLT3 inhibitor (usually midostaurin)
Study: NCT04676243
Drug: Standard of Care Chemotherapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Daunorubicin/ Cytarabine or Idarubicin/Cytarabine
Study: NCT06394063
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo to Telitacicept
Study: NCT06056973
Drug: jinghua weikang capsule
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral Jinghua Weikang Capsule, two capsules each time, three times a day
Study: NCT06256419
Drug: GLP-1 receptor agonist
Normalized name: GLP-1 receptor agonist
Approvals — FDA: no, EMA: no, PMDA: no
Description: Eligible patients with T2DM were required to have received GLP-1RA as monotherapy or in combination with other antidiabetic agents. GLP-1 RA was injected subcutaneously at standard dose and frequency for consecutive 6 months in patients with T2DM.
Study: NCT05463133
Drug: Cyclophosphamide
Normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Post transplant drug - cyclophosphamide give to prevent graft versus host disease. This is a well studied drug and s not under an IND.
Study: NCT05463133
Drug: Total Body Irradiation
Normalized name: Colgate Total Mouthwash
Approvals — FDA: no, EMA: no, PMDA: no
Description: Transplant Conditioning - Total Body Irradiation (300 cGy in fractionated doses) to create space n the subject's bone marrow so that the donor peripheral blood stem cells can repopulate in the subject's bone marrow.
Study: NCT05597735
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: The control intervention is a placebo and its route of administration will be identical to the experimental intervention administration to allow treatment arm blinding.
Study: NCT06127212
Drug: Forxiga® 10 mg Film-Coated Tablet, manufactured by AstraZeneca Pharmaceuticals LP, USA for AstraZeneca Pharmaceuticals Co. Ltd., China imported by PT AstraZeneca Indonesia, Indonesia
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet of the reference drug was given orally (swallowed with 240 mL of 20% glucose solution in water), after an overnight fast.
Study: NCT04943211
Drug: fluorodeoxyglucose (18F-FDG)
Normalized name: fluorodeoxyglucose F18
Approvals — FDA: no, EMA: no, PMDA: no
Description: max 6 MGBq/kg, no more than 100
Study: NCT05332444
Drug: susceptibility-guided tailored therapy (Group A)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: Includes 5 treatment options. The priority order of treatment regimens is based on the selection principal through AST with MIC profile.~1. clarithromycin triple therapy: include rabeprazole 20mg bid, amoxicillin 1 g bid, and clarithromycin 500 mg bid, for 14 days; or 2. levofloxacin triple therapy: include rapeprazole 20 mg bid, amoxicillin 1 g bid, and levofloxacin 500 mg bid, for 14 days; or 3. metronidazole triple therapy: include rabeprazole 20 mg bid, amoxicillin 500 mg qid, and metronidazole 250 mg qid, for 14 days; or 4. high-dose dual therapy: include rabeprazole 20 mg qid, amoxicillin 750 mg qid, for 14 days; or 5. bismuth quadruple therapy: include rabeprazole 20 mg bid, bismuth 120 mg qid, metronidazole 500 mg tid, and tetracycline 500 mg qid, for 14 days.
Study: NCT05332444
Drug: guidelines-recommended empiric therapy (Group B)
Normalized name: Monistat Simple Therapy
Approvals — FDA: no, EMA: no, PMDA: no
Description: bismuth quadruple therapy: include rabeprazole 20 mg bid, bismuth 120 mg qid, metronidazole 500 mg tid, and tetracycline 500 mg qid, for 14 days.
Study: NCT05755789
Drug: Continuous infusion of placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Continuous infusion of placebo from the end of the loading bolus until the end of surgical closure
Study: NCT05755789
Drug: Intermittent placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Additional bolus of placebo every 2 hours until the end of surgical closure
Study: NCT05690321
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Self-administration of placebo (10 mg/ml) as 3x5 drops on day 1-3, 3x10 drops on days 4-6, and 1x10 drops on day 7 in each study period
Study: NCT05282940
Drug: Microgynon CD
Approvals — FDA: no, EMA: no, PMDA: no
Description: Microgynon CD will be used as a comparator drug for the BE study. Other Name: Levonorgestrel 15.0 mg and Ethinyl estradiol 0.03 mg Reference Drug
Study: NCT05219812
Drug: BAY2395840
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, intake orally.
Study: NCT05219812
Drug: Placebo for BAY2395840
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tablet, intake orally.
Study: NCT06205134
Drug: A: Epinephrine injection
DrugBank: Epinephrine (DB00668)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Autoinjector for intramuscular, single-use, 0.3mg
Study: NCT06205134
Drug: B: FMXIN002 3.6mg
Approvals — FDA: no, EMA: no, PMDA: no
Description: Nasus Pharma nasal powder spray 3.6 mg, single use in one nostril
Study: NCT06342921
Drug: 15 mg ADC189
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use only once during the whole study.
Study: NCT06342921
Drug: 45 mg ADC189
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use only once during the whole study.
Study: NCT06342921
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Use only once during the whole study.
Study: NCT06170333
Drug: 8% sulphur and A. vera soap
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients in experimental arms will receive the combination of 8% sulphur and A. vera soap for four weeks along with 2% ketoconazole shampoo for a week.
Study: NCT05927129
Drug: Antidepressant
Normalized name: Antidepressant
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients will receive standardized treatment with antidepressant, and their treatment efficacy will be assessed by a blinded psychological assessor using validated rating scales. The assessment will be conducted monthly, and evaluations will be tracked for a period of three months.
Study: NCT05215574
Drug: NGM831
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug: NGM831 NGM831 is given intravenously (IV) every 3 weeks in a 21 day cycle. Multiple dose levels will be evaluated.
Study: NCT00002365
Drug: LXR015-1
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05203965
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Two matching tablets of placebo will be administered on the morning of one of the two experimental days by an RN or the physician investigator.
Study: NCT04946318
Drug: CSJ117
Approvals — FDA: no, EMA: no, PMDA: no
Description: CSJ117 (0.5 mg, 1mg, 2mg, 4 mg and 8 mg) capsules for inhalation once daily delivered via Concept1 inhalation device for 12 or 24 weeks.
Study: NCT04946318
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo inhaled once daily for 12 or 24 weeks. Delivered via Concept1 device.
Study: NCT04746040
Drug: Test
Normalized name: Testro
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 inhalations of Test and Reference product in each study period
Study: NCT04746040
Drug: Reference
Normalized name: Loreal Preference Dark Auburn 4R
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 inhalations of Test and Reference product in each study period
Study: NCT06353646
Drug: Chemotherapy
Normalized name: Chemotherapy Glove SML
Approvals — FDA: no, EMA: no, PMDA: no
Description: gemcitabine + capecitabine
Study: NCT05437094
Drug: CRD-740
Approvals — FDA: no, EMA: no, PMDA: no
Description: CRD-740
Study: NCT04590612
Drug: Carbidopa-Levodopa 25 Mg-100 Mg Oral Tablet
Normalized name: carbidopa-levodopa 25 mg-100 mg oral tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: 25mg-100mg tablets to be taken orally three times a day on an empty stomach
Study: NCT05292677
Drug: Steroid/Anesthesia Mixture
Approvals — FDA: no, EMA: no, PMDA: no
Description: Steroid will be Triamcinolone Acetonide (40mg/mL). Anesthetic will be 0.5% bupivacaine with 1:100,000 epinephrine. These will be pre-mixed by a qualified personnel within the ENT department.
Study: NCT05292677
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL of Normal Saline
Study: NCT05539053
Drug: N Acetylcysteine A
Approvals — FDA: no, EMA: no, PMDA: no
Description: paclitaxel + N-Acetylcysteine orally short course
Study: NCT05539053
Drug: N Acetylcysteine B
Approvals — FDA: no, EMA: no, PMDA: no
Description: paclitaxel +N Acetylcysteine orally long course
Study: NCT06449625
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: semaglutide placebo
Study: NCT04124367
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 100 ml once daily 0.9% saline
Study: NCT00411515
Drug: Mycophenolate Mofetil 2x 1g
Normalized name: Mycophenolate Mofetil
DrugBank: Mycophenolate mofetil (DB00688)
Approvals — FDA: yes, EMA: no, PMDA: yes
Study: NCT05569577
Drug: Additional hCG injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: An additional hCG injection of 2000-5000IU would be given 48 hours following routine hCG trigger and ovulation for LPS on the basis of supplementation of estrogen and dydrogesterone.
Study: NCT05475873
Drug: normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: A bolus of normal saline (2 ml) by IV was given 5 min before spinal anesthesia.
Study: NCT06217406
Drug: Saline bags
Approvals — FDA: no, EMA: no, PMDA: no
Description: Patients randomized in the control arm will receive placebo, eg. saline bags (same volume as acyclovir bags) every 8 hours during 14 days (treatment will be stopped in case of ICU discharge).
Study: NCT06510426
Drug: Rebif 44 MCG Per 0.5 ML Prefilled Syringe
Normalized name: Rebif 44 MCG per 0.5 ML Prefilled Syringe
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rebif 44mcg per 0.5ml administered subcutaneously
Study: NCT05778318
Drug: The group of patients who received Lianhua Qingwen orally
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lianhua Qingwen Granules: oral. One bag at a time, three times a day. The course of treatment for mild and ordinary cases of novel coronavirus pneumonia is 7-10 days.
Study: NCT06656988
Drug: CO2
Normalized name: CO2 (ISBT symbol)
Approvals — FDA: no, EMA: no, PMDA: no
Description: CO2 will be used as contrast medium sparing strategy during peripheral angiography
Study: NCT06656988
Drug: Iodinated Contrast Media (ICM)
Normalized name: Stellaria media extract
Approvals — FDA: no, EMA: no, PMDA: no
Description: Iodinated contrast medium will be used as in routine care during peripheral angiography
Study: NCT06046560
Drug: SGLT2 inhibitor, GLP-1 RA
Approvals — FDA: no, EMA: no, PMDA: no
Description: Immediate initiation of guideline-directed medical therapy. Will also immediately receive the same educational services provided in the Education-First intervention.
Study: NCT05136391
Drug: XTR003
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of 8.0-10 mCi of XTR003 will be injected on the first day of the study (Day 1). Serial whole-body PET imaging will be acquired after dose injection.
Study: NCT06535126
Drug: CanProFem-AK
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dosage form - vaginal suppositories (100 mg). Dosage regimen - single intravaginal administration of suppository. Vaginal suppositories are inserted as deeply as possible while the participant is lying down; the participant must remain in a horizontal position for 45 minutes after the administration. The total duration of volunteer participation in the study is one day. Medical observation (including gynaecological monitoring with vaginal bacterial swab test) of the subject condition after the drug administration will be carried out after 3, 6, 9, 12 and 24 hours. Repeated laboratory blood and urine tests will be performed after 24 hours. Participants of the study will be closely monitored for 24 hours after the initial administration of the drug to detect any immediate adverse events. If the subject experiences an immediate adverse event, appropriate treatment will be provided.
Study: NCT05128617
Drug: Epirubicin-cyclophosphamide
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 cycle of Epirubicin-cyclophosphamide
Study: NCT04723537
Drug: Part A and B: Placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 or 2 capsules, each capsule a matching placebo
Study: NCT05027269
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered by intravenous (IV) infusion.
Study: NCT05965570
Drug: Clarithromycin
Normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Oral tablets.
Study: NCT01231191
Drug: Intravenous acetaminophen
Normalized name: Acetaminophen
DrugBank: Acetaminophen (DB00316)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Acetaminophen 1000 mg administered over 15 minutes intravenously as soon as feasible intraoperatively.
Study: NCT01231191
Drug: Intravenous placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline administered over 15 minutes intravenously as soon as feasible intraoperatively.
Study: NCT05959499
Drug: BR6002A
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet administered alone
Study: NCT06256419
Drug: responders group and nonresponders group
Normalized name: Streptococcus viridans group
Approvals — FDA: no, EMA: no, PMDA: no
Description: For all the patients with type 2 diabetes who were initially enrolled in the study, blood samples were obtained for genotyping before the administration of GLP-1 receptor agonists. Patients were re-screened according to whether they had used GLP-1 RA continuously for more than 6 months and had completed the specified follow-up tasks.~Patients were divided according to the type of T2DM susceptibility genes. Or all were divided into responses group and nonresponses group according to whether they had glycemic response (△HbA1c↓ ≥1.0%) and weight response (△weight↓ ≥3.0%) after taking GLP-1 receptor agonist for 6 months.~According to the above grouping, the variables that can predict the efficacy of the drug were identified, and the weight of the influence of these variables on the efficacy was evaluated.
Study: NCT04897763
Drug: 89Zr-TLX250 PET/CT
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pretherapeutic 89Zr-TLX250 PET/CT
Study: NCT05959499
Drug: BR6002B
Approvals — FDA: no, EMA: no, PMDA: no
Description: One tablet administered alone
Study: NCT05959499
Drug: BR6002
Approvals — FDA: no, EMA: no, PMDA: no
Description: One capsule administered alone
Study: NCT04837040
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo, tablets, once daily by mouth
Study: NCT05015894
Drug: NNC0480-0389
Approvals — FDA: no, EMA: no, PMDA: no
Description: A single dose of 18 mg NNC0480 0389 administered subcutaneously (under the skin).~Total duration of study participation for each participant is 38 to 66 days
Study: NCT00960817
Drug: Statin, aspirin
Approvals — FDA: no, EMA: no, PMDA: no
Study: NCT05513976
Drug: SHR4640 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR4640 tablet 5mg
Study: NCT05513976
Drug: SHR4640 tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR4640 tablet 10mg
Study: NCT05513976
Drug: SHR4640 placebo tablet
Normalized name: PLACEBO TAB
Approvals — FDA: no, EMA: no, PMDA: no
Description: SHR4640 placebo tablet 5 or 10mg
Study: NCT06498037
Drug: Fentanyl
Normalized name: Fentanyl
DrugBank: Fentanyl (DB00813)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Administration of subcutaneously administered fentanyl loading boluses
Study: NCT06255886
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo medicine (appearing substantially like Omeprazole) 1mg/ ml, and continuing nutrition containing cows' milk protein
Study: NCT04885049
Drug: DiaResQ Children's Powder for Suspension
Normalized name: DiaResQ Children's Powder for Suspension
Approvals — FDA: no, EMA: no, PMDA: no
Description: oral immunoglobulins
Study: NCT05926206
Drug: Modified FOLFIRINOX
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oxaliplatin- 85 mg/m2, IV over 120 minutes, day 1 Leucovorin/folinic acid- 400 mg/m2, IV over 90 minutes, day 1 Irinotecan- 150 mg/m2, IV over 90 minutes, day 1 5FU- 2400 mg/m2, IV over 42-48 hours after irinotecan, day 1
Study: NCT05170737
Drug: AEF0217
Approvals — FDA: no, EMA: no, PMDA: no
Description: PART I: A total of 32 healthy male and female subjects will be randomized into four consecutive single ascending dose cohorts of 8 subjects. The study will have 4 different doses of AEF0217 (0.2, 0.6, 2 \& 6 mg) and 1 dose of matching placebo. A given subject can be randomized only in one dose level cohort.~PART II: A total of 24 healthy subjects will be randomized in three consecutive multiple ascending dose cohorts of 8 subjects. The study will have 3 different doses of AEF0217 (0.6, 2 \& 6 mg) and 1 dose of matching placebo. Doses could be modified following the results of FIH-SAD. A given subject can be randomized only in one dose level cohort.~PART III: A total of 12 healthy male subjects will be randomly assigned to one of two sequences in the crossover study part. All subjects will receive the same dose of AEF0117 which will be determined following the results of the FIH-SAD.
Study: NCT05170737
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PART I: A total of 32 healthy male and female subjects will be randomized into four consecutive single ascending dose cohorts of 8 subjects. The study will have 4 different doses of AEF0217 (0.2, 0.6, 2 \& 6 mg) and 1 dose of matching placebo. A given subject can be randomized only in one dose level cohort.~PART II: A total of 24 healthy subjects will be randomized in three consecutive multiple ascending dose cohorts of 8 subjects. The study will have 3 different doses of AEF0217 (0.6, 2 \& 6 mg) and 1 dose of matching placebo. Doses could be modified following the results of FIH-SAD. A given subject can be randomized only in one dose level cohort.
Study: NCT05650229
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Twice daily
Study: NCT05383677
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo will be administered in intravenous infusions once per 4 weeks, for a total treatment period of 24 weeks.
Study: NCT06572917
Drug: Indomethacin
Normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Single dose of 0.1 mg/kg dose intravenous indomethacin as a slow infusion over 20 mins
Study: NCT06572917
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Single dose of intravenous normal saline placebo as a slow infusion over 20 mins
Study: NCT05509257
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Participants will receive a single oral dose of medication in randomized, crossover fashion with a 2 week wash out period between interventions.. Medication will be taken 2 hours prior the neuroimaging.
Study: NCT06562816
Drug: Naproxen Sodium 550mg
Normalized name: Naproxen Sodium 550mg Oral tablet
DrugBank: Naproxen (DB00788)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: 550mg
Study: NCT05058872
Drug: Levonorgestrel/ethinyl estradiol
Normalized name: levonorgestrel/ethinyl estradiol 0.1 mg-20 mcg ORAL TABLET
Approvals — FDA: no, EMA: no, PMDA: no
Description: Levonorgestrel 0.15mg/ethinyl estradiol 0.03mg
Study: NCT05058872
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo comparator
Study: NCT05360615
Drug: Placebo
Normalized name: placebo
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo
Study: NCT05595473
Drug: RZ-001 Dose 1
Approvals — FDA: no, EMA: no, PMDA: no
Description: RZ-001 Dose 1 and VGCV
Study: NCT05595473
Drug: RZ-001 Dose 2
Approvals — FDA: no, EMA: no, PMDA: no
Description: RZ-001 Dose 2 and VGCV
Study: NCT05595473
Drug: RZ-001 Dose 3
Approvals — FDA: no, EMA: no, PMDA: no
Description: RZ-001 Dose 3 and VGCV